<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086708</url>
  </required_header>
  <id_info>
    <org_study_id>2010P000705</org_study_id>
    <nct_id>NCT02086708</nct_id>
  </id_info>
  <brief_title>Ultrasound Method to Measure Fibrosis of the Liver in Children</brief_title>
  <official_title>Sonoelastography: Ultrasound Method to Measure Fibrosis of the Liver in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate
      quantitative measurements that can be used to stage liver fibrosis in pediatric patients with
      chronic liver disease.

      Specific Aims:

      To measure liver stiffness with sonoelastography in pediatric and adolescents with suspect
      diffuse liver disease who will undergo nonfocal liver biopsy as part of their routine
      clinical care.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The technology showed rapid acceptance in the general population and we halted our feasibility
    demonstration study.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Liver Elasticity Value Using Sonoelastography.</measure>
    <time_frame>Day one</time_frame>
    <description>Assess liver stiffness as measured by sonoelastography with results of liver biopsy as read by a single-pathologist using the METAVIR criteria (F0-F4).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>HCV Coinfection</condition>
  <condition>HBV</condition>
  <condition>Drug-Induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>Shear Wave Sonoelastography, Fibrosis stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shear Wave sonoelastography</intervention_name>
    <description>Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.</description>
    <arm_group_label>Shear Wave Sonoelastography, Fibrosis stage</arm_group_label>
    <other_name>Supersonic Aixplorer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients scheduled for random liver biopsy for routine staging of liver fibrosis

          -  Pediatric patients patients (ages 1-21)

          -  Girls or boys

          -  Suspected liver disease

          -  Consent to participate in the study

        Exclusion criteria:

          -  Pregnancy

          -  Acute illness/cognitive impairment resulting in inability to cooperate with ultrasound

          -  Patients that do not consent to ultrasound guided liver biopsy.

          -  Contraindications to liver biopsy (e.g. low platelets defined as a platelet count of
             less than 50,000, and hemophilia/coagulopathy as an INR higher than 1.5.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uzma Shah, MD, FAAP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetss General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dhyani M, Gee MS, Misdraji J, Israel EJ, Shah U, Samir AE. Feasibility study for assessing liver fibrosis in paediatric and adolescent patients using real-time shear wave elastography. J Med Imaging Radiat Oncol. 2015 Dec;59(6):687-94; quiz 751. doi: 10.1111/1754-9485.12388. Epub 2015 Oct 27.</citation>
    <PMID>26503488</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>October 5, 2016</results_first_submitted>
  <results_first_submitted_qc>December 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2017</results_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Uzma Shah, MD</investigator_full_name>
    <investigator_title>Associate Professor in Pediatrics, Massachusetts General Hospital for Children, Harvard Medi</investigator_title>
  </responsible_party>
  <keyword>Sonoelastography,</keyword>
  <keyword>Diffuse liver disease,</keyword>
  <keyword>chronic liver disease,</keyword>
  <keyword>NASH,</keyword>
  <keyword>NAFLD,</keyword>
  <keyword>Elevated Transaminases,</keyword>
  <keyword>Liver Biopsy,</keyword>
  <keyword>Fibrosis,</keyword>
  <keyword>METAVIR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1. Patients scheduled for Liver Biopsy 2.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Shear Wave Sonoelastography, Fibrosis</title>
          <description>Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
Shear Wave sonoelastography: Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score from liver biopsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pediatric and Adolescents</population>
      <group_list>
        <group group_id="B1">
          <title>Shear Wave Sonoelastography, Fibrosis</title>
          <description>Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
Shear Wave sonoelastography: Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score from liver biopsy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>In this study:
The eligibility age range was 1-21 years.
We enrolled subjects with the age with the minimum age value of 1 years and the maximum age value of 21 years.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Liver Elasticity Value Using Sonoelastography.</title>
        <description>Assess liver stiffness as measured by sonoelastography with results of liver biopsy as read by a single-pathologist using the METAVIR criteria (F0-F4).</description>
        <time_frame>Day one</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fibrosis 0</title>
            <description>Patients with no Fibrosis on liver biopsy evaluation</description>
          </group>
          <group group_id="O2">
            <title>Fibrosis 1</title>
            <description>Patients with liver biopsy METAVIR stage 1 on pathology evaluation</description>
          </group>
          <group group_id="O3">
            <title>Fibrosis 2</title>
            <description>Patients with liver biopsy METAVIR stage 2 on pathology evaluation</description>
          </group>
          <group group_id="O4">
            <title>Fibrosis 3</title>
            <description>Patients with liver biopsy METAVIR stage 3 on pathology evaluation</description>
          </group>
          <group group_id="O5">
            <title>Fibrosis 4</title>
            <description>Patients with liver biopsy METAVIR stage 4 on pathology evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Liver Elasticity Value Using Sonoelastography.</title>
          <description>Assess liver stiffness as measured by sonoelastography with results of liver biopsy as read by a single-pathologist using the METAVIR criteria (F0-F4).</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="6.33" upper_limit="7.44"/>
                    <measurement group_id="O2" value="8.33" lower_limit="6.83" upper_limit="10.80"/>
                    <measurement group_id="O3" value="6.12">For 1 subject, 95% confidence intervals cannot be calculated.</measurement>
                    <measurement group_id="O4" value="8.86" lower_limit="5.7" upper_limit="11.4"/>
                    <measurement group_id="O5" value="17.85">For 1 subject, 95% confidence intervals cannot be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fibrosis 0</title>
          <description>Patients with no Fibrosis on liver biopsy evaluation</description>
        </group>
        <group group_id="E2">
          <title>Fibrosis 1</title>
          <description>Patients with liver biopsy METAVIR stage 1 on pathology evaluation</description>
        </group>
        <group group_id="E3">
          <title>Fibrosis 2</title>
          <description>Patients with liver biopsy METAVIR stage 2 on pathology evaluation</description>
        </group>
        <group group_id="E4">
          <title>Fibrosis 3</title>
          <description>Patients with liver biopsy METAVIR stage 3 on pathology evaluation</description>
        </group>
        <group group_id="E5">
          <title>Fibrosis 4</title>
          <description>Patients with liver biopsy METAVIR stage 4 on pathology evaluation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was meant to be a feasibility study to show that shear-wave sonoelastography can be performed in the pediatric age group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Uzma Shah</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1450</phone>
      <email>USHAH@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

